Lymphoma, Large B-Cell, Diffuse: all 1,432 studies

Page 8 of 15. Open to participants first (359), then studies with results posted, then the rest; newest registration first within each.

• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Phase 3
• BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.Active, not recruitingNCT06424379
• Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS DataCompletedNCT06392763
• Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic MalignanciesTerminatedNCT06343376Phase 1
• Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe NeutropeniaActive, not recruitingNCT06323447
• PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCLWithdrawnNCT06290622Phase 1
• Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)Active, not recruitingNCT06285422Phase 1
• Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.CompletedNCT06271369
• A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT06256484Phase 1
• A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersTerminatedNCT06254495Phase 1
• Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2
• CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell LymphomaActive, not recruitingNCT06149169Phase 2
• Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapyCompletedNCT06141772Not applicable
• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersTerminatedNCT06120504Phase 1
• Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLActive, not recruitingNCT06093841Phase 2
• Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma SubjectsCompletedNCT06074107Phase 2
• Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell LymphomaCompletedNCT06031194
• P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell MalignanciesActive, not recruitingNCT06014762Phase 1
• Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With KymriahWithdrawnNCT06003179Phase 1
• R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell LymphomaWithdrawnNCT05966233Phase 2
• Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLCompletedNCT05958134
• A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell LymphomaActive, not recruitingNCT05954910
• Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaCompletedNCT05940064Phase 2
• A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell LymphomasActive, not recruitingNCT05934838Phase 1
• FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaWithdrawnNCT05934097Phase 1
• Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient SettingsCompletedNCT05918809
• A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedNCT05896163Phase 1/2
• Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)Active, not recruitingNCT05878184Phase 1
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesTerminatedNCT05828589Phase 1
• Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaActive, not recruitingNCT05821088Phase 2
• Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPActive, not recruitingNCT05798156Phase 2
• Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT05786989Phase 4
• R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05784987Not applicable
• Observational Study of People Living With HIV Treated With CD19-directed CAR T CellCompletedNCT05784415
• R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaStatus unknownNCT05777369Not applicable
• Phase I/IIa Study of BR1733 in Subjects With Advanced CancersActive, not recruitingNCT05749549Phase 1/2
• Expanded Access Program for EpcoritamabApproved for marketingNCT05733650
• Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With AnthracyclinesStatus unknownNCT05728632Phase 3
• Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell TherapyActive, not recruitingNCT05725720
• A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaTerminatedNCT05720052Phase 1/2
• Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesCompletedNCT05694364Phase 1
• A Rollover Study of CC-122Active, not recruitingNCT05688475Phase 1
• Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T CellsActive, not recruitingNCT05675982Not applicable
• The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell LymphomaStatus unknownNCT05673447Early Phase 1
• A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
• Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesActive, not recruitingNCT05665062Phase 1
• Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaTerminatedNCT05660967Phase 2
• A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)TerminatedNCT05660395Phase 1
• A Study of MT-2111 in Patients With Relapsed/Refractory DLBCLActive, not recruitingNCT05658562Phase 1/2
• Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.TerminatedNCT05645744
• Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT05618366Phase 1
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsActive, not recruitingNCT05618028Phase 1
• Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesTerminatedNCT05611853Phase 1/2
• A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT05578976Phase 3
• Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasActive, not recruitingNCT05565417Phase 1/2
• Study of Oral MRT-2359 in Selected Cancer PatientsActive, not recruitingNCT05546268Phase 1/2
• Comparison of Clinical Outcomes Among Patients Treated With TisagenlecleucelCompletedNCT05541328
• Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T CellsStatus unknownNCT05532761
• A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP TherapyStatus unknownNCT05527912Phase 2
• A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT05512390Phase 1
• TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT05507541Phase 2
• Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCLStatus unknownNCT05498259Phase 2
• Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingNCT05455697Phase 1/2
• Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05453396Phase 2
• A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaActive, not recruitingNCT05451810Phase 2
• Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingNCT05429268Phase 3
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05421663Phase 1/2
• Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell LymphomaActive, not recruitingNCT05412290Phase 1
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)Active, not recruitingNCT05406401Phase 2
• Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
• Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT05366257
• A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaCompletedNCT05364424Phase 1
• NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell LymphomaCompletedNCT05359211Phase 1
• A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT05354362Phase 1
• CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)CompletedNCT05349201
• Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT05338892
• A Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesTerminatedNCT05336409Phase 1
• GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
• Fatigue Reduction Diet in Lymphoma SurvivorsCompletedNCT05327725Not applicable
• Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell LymphomaActive, not recruitingNCT05326243Phase 1/2
• Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT05319028Phase 2
• Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell LymphomaCompletedNCT05318391
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingNCT05283720Phase 2
• Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCLStatus unknownNCT05269914Not applicable
• A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLTerminatedNCT05265975Phase 1/2
• Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaActive, not recruitingNCT05263583Phase 2
• Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLCompletedNCT05233033Phase 1
• Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT05228249Phase 1
• Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post TransplantWithdrawnNCT05222438Phase 2
• Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT05221645Phase 2
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaStatus unknownNCT05208853Early Phase 1
• Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabActive, not recruitingNCT05206357Phase 1
• Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
• A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
• Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With TisagenlecleucelTerminatedNCT05199961Not applicable
• A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT05192486Phase 1/2
• Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05189782
• A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double ExpressionActive, not recruitingNCT05189197Phase 2
• A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)TerminatedNCT05169489Phase 1
• The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry StudyCompletedNCT05169203

← Lymphoma, Large B-Cell, Diffuse overview